MedTrace Logo

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

NCT01827462 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2017-07-11

Study results available
· View outcomes & findings →

Summary

In this study the investigators are trying to understand how immune function declines in the elderly using annual influenza vaccinations as a model system. The longitudinal study began in 2007 and continued through early 2017.

Conditions

Interventions

BIOLOGICAL

Trivalent, inactivated influenza vaccine (TIV)

Licensed Seasonal Influenza Vaccine TIV

BIOLOGICAL

Quadrivalent, inactivated influenza vaccine (IIV4)

Licensed Seasonal Influenza Vaccine IIV4

BIOLOGICAL

High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)

Licensed Seasonal High-Dose Influenza Vaccine TIV

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Cornelia L Dekker, MD · Stanford University

  • Mark M Davis, PhD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2015-12-31
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01827462 on ClinicalTrials.gov